Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | DPV-001 |
Trade Name | |
Synonyms | DPV 001|DPV001 |
Drug Descriptions |
DPV-001 is a cancer vaccine consisting of dendritic cell targeting microvesicles (DRibbles), which are autophagosomes derived from two non-small cell lung carcinoma cell lines (UbiLT3 and UbiLT6) that contain numerous tumor-associated antigens, including DAMPs, and delivers stable short-lived proteins (SLiPs) and defective ribosomal products (DRiPs), potential resulting in the induction of antitumor immune response (JITC 2015; 3(Suppl 2): P435; JITC 2013; 1(Suppl 1): P260). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C107681 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
DPV-001 | DPV-001 | 0 | 0 |
DPV-001 + INCAGN01876 + Retifanlimab | DPV-001 INCAGN01876 Retifanlimab | 0 | 1 |
DPV-001 + INCAGN01949 + Retifanlimab | DPV-001 INCAGN01949 Retifanlimab | 0 | 0 |
DPV-001 + Retifanlimab | DPV-001 Retifanlimab | 0 | 1 |